Mycophenolate mofetil prevents arteriolopathy and renal injury in subtotal ablation despite persistent hypertension

Kidney International

Volumn 63, Issue 3, 2003, Pages 994-1002

  Tapia, Edilia ^a   Franco, Martha ^b   Sánchez Lozada, Laura G ^b   Soto, Virgilia ^b   Avila Casado, Carmen ^b   Santamaría, José ^b   Quiroz, Yasmir ^b   Rodríguez Iturbe, Bernardo ^b   Herrera Acosta, Jaime ^b  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b NONE

Author keywords

5 6 nephrectomy; Arteriolopathy; Glomerular hemodynamics; Inflammation; Mycophenolate mofetil

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; CAPILLARY PRESSURE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; GLOMERULOSCLEROSIS; GLOMERULUS; GLOMERULUS CAPILLARY; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HYPERTENSION; HYPERTROPHY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY BLOOD FLOW; KIDNEY INJURY; LYMPHOCYTE; MACROPHAGE; MALE; MEAN ARTERIAL PRESSURE; MORPHOMETRICS; NEPHRECTOMY; NEPHRON; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEINURIA; PUNCH BIOPSY; RAT; ULTRAFILTRATION; VASCULAR DISEASE; VASCULAR RESISTANCE;

EID: 0037338439     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00811.x     Document Type: Article

References (46)

1. RUGGENENTI P, REMUZZI G: The role of protein traffic in the progression of renal diseases. Annu Rev Med 51:315-327, 2000
2. BAKRIS GL, WILLIAMS M, DWORKIN L, et al: Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36:646-661, 2000
3. ANDERSON S, MEYER TW, RENNKE HG, BRENNER BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76:612-619, 1985
4. MEYER TW, RENNKE HG: Progressive glomerular injury after limited renal infarction in the rat. Am J Physiol 254:F856-F862, 1988
5. TAPIA E, GABBAI FB, CALLEJA C, et al: Determinants of renal damage in rats with systemic hypertension and partial renal ablation. Kidney Int 38:642-648, 1990
6. HOSTETTER TH, OLSON JL, RENNKE HG, et al: Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 241:F85-F93, 1981
7. ABBATE M, ZOJA C, CORNA D, et al: In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol 9:1213-1224, 1998
8. MÜLLER DN, DECHEND R, MERVAALA EMA, et al: NF-κB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertens 35:193-201, 2000
9. MÜLLER DN, HEISSMEYER V, DECHEND R, et al: Aspirin inhibits NF-κB and protects from angiotensin II-induced organ damage. FASEB J15:1822-1824, 2001
10. FUJIHARA CK, MALHEIROS DM, ZATZ R, NORONHA ID: Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 54:1510-1519, 1998
11. ROMERO F, RODRÍGUEZ-ITURBE B, PARRA G, et al: Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 55:945-955, 1999
12. FUJIHARA CK, AVANCINI DM, NORONHA IL, et al: Mycophenolate mofetil reduces renal injury in the chronic nitric oxide synthase inhibition model. Hypertens 37:170-175, 2001
13. ZOJA C, BENIGNI A, REMUZZI G: Protein overload activates proximal tubular cells to release vasoactive and inflammatory mediators. Exp Nephrol 7:420-428, 1999
14. FRANCO M, TAPIA E, SANTAMARÍA J, et al: Renal cortical vasoconstriction contributes to development of salt-sensitive hypertension after angiotensin II exposure. J Am Soc Nephrol 12:2263-2271, 2001
15. ZOJA C, CORNA D, ROTTOLI D, et al: Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int 61:1635-1645, 2002
16. PARK JK, MÜLLER DM, MERVAALA EMA, et al: Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int 58:1420-1430, 2000
17. FUJIHARA CK, NORONHA ID, AVANCINI DM, et al: Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 11:283-290, 2000
18. FUJIHARA CK, MALHEIROS DMAC, DONATO JL, et al: Nitroflurbiprofen, a new nonsteroidal anti-inflammatory, ameliorates structural injury in the remnant kidney. Am J Physiol 274:F573-F579, 1998
19. BOBADILLA NA: Tack I, Tapia E, et al: Pentosan polysulfate prevents glomerular hypertension and structural injury despite persisting hypertension in 5/6 nephrectomy rats. J Am Soc Nephrol 12:2080-2087, 2001
20. REMUZZI G, ZOJA C, GAGLIARDINI E, et al: Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 10:1542-1549, 1999
21. ALLISON AC, EUGUI EM: Mycophenolate mofetil a rationally designed immunosuppressive drug. Clin Transplant 7:96-112, 1993
22. DAVIDSON WD, SACKNER MA: Simplification of the anthrone method for the determination of inulin in clearance studies. J Lab Clin Med 62:351-356, 1963
23. VUREK GG, PEGRAM SE: Fluorometric method for the determination of nanogram quantities of inulin. Anal Biochem 16:409-419, 1966
24. VIETS JW, DEEN WM, TROY JL, BRENNER BM: Determination of serum protein concentration in nanoliter blood samples using fluorescamine or o-phtalaldehyde. Anal Biochem 88:513-521, 1978
25. HENRY RJ, SOBEL CH, SEGALOVE M: Turbidimetric determination of proteins with sulfosalicylic and trichloroacetic acids. Proc Soc Exp Biol Med 92:748-751, 1956
26. BAYLIS C, DEEN WM, MYERS BD, BRENNER BM: Effects of some vasodilator drugs on transcapillary fluid exchange in renal cortex. Am J Physiol 230:1148-1158, 1976
27. RAIJ L, AZAR S, KEANE W: Mesangial immune injury, hypertension and progressive damage in Dahl rats. Kidney Int 26:137-143, 1984
28. QUIROZ Y, PONS H, GORDON KL, et al: Mycophenolate mofetil prevents salt- sensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol 281:F38-F47, 2001
29. MAZZALI M, FENG L, KANG DH, et al: Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure independent mechanism. Am J Physiol 282:F991-F997, 2002
30. SÁNCHEZ-LOZADA LG, TAPIA E, AVILA-CASADO C, et al: Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol 283:F1105-F1110, 2002
31. MULVANY MJ: Vascular remodeling of resistance vessels: Can we define this? J Cardiovasc Res 41:9-13, 1999
32. SCHIFFRIN EL, HAYOZ D: How to assess vascular remodeling in small and medium sized arteries in humans. J Hypertens 15:571-584, 1997
33. PARRA G, MORENO P, RODRÍGUEZ-ITURBE B: Glomerular proliferative activity and T lymphocyte infiltration in acute serum sickness. Clin Immunol Immunopathol 82:299-302, 1997
34. RINCÓN J, PARRA G, QUIROZ Y, et al: Cyclosporine A reduces the expression of adhesion molecules in the kidney of rats with chronic serum sickness. Clin Exp Immunol 121:391-398, 2000
35. YU CC, YANG CW, WU MS, et al: Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice. J Lab Clin Med 138:69-77, 2001
36. KLIEM V, JOHNSON RJ, ALPERS CE, et al: Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int 49:666-678, 1996
37. DEEN WM, TROY JL, ROBERTSON CR, et al: Dynamics of glomerular ultrafiltration in the rat. IV. Determination of ultrafiltration coefficient. J Clin Invest 52:1500-1508, 1973
38. BLANTZ RC, KONNEN KS, TUCKER BJ: Angiotensin II effects upon the glomerular microcirculation and ultrafiltration coefficient in the rat. J Clin Invest 57:419-434, 1976
39. BAYLIS C, BRENNER BM: The physiologic determinants of glomerular ultrafiltration. Rev Physiol Biochem Pharmacol 80:2-46, 1978
40. MERVAALA E, MÜLLER D, SCHMIDT F. et al: Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension 35:587-594, 2000
41. LUFT FC: Mechanisms and cardiovascular damage in hypertension. Hypertension 37:594-598, 2001
42. TOUYZ RM, HE G, EL MABROUK M, SCHIFFRIN EL: p38 MAP kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY. Hypertension 37:574-580, 2001
43. BADID C, VINCENT M, MCGREGOR B, et al: Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 58:51-61, 2000
44. GREGORY CR, HUANG X, PRATT RE, et al: Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 59:655-661, 1995
45. GREGORY CR, PRATT RE, HUIE P, et al: Effects of treatment with cyclosporin, FK-506, rapamycin, mycophenolic acid or desoxispergualin on vascular muscle proliferation in vitro and in vivo. Transplant Proc 25:770-771, 1993
46. ALLISON AC, EUGUI EM: Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47:84-118, 2000